Biomarkers to Distinguish Bacterial From Viral Pediatric Clinical Pneumonia in a Malaria-Endemic Setting.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
06 12 2021
Historique:
received: 30 06 2020
pubmed: 4 2 2021
medline: 15 3 2022
entrez: 3 2 2021
Statut: ppublish

Résumé

Differential etiologies of pediatric acute febrile respiratory illness pose challenges for all populations globally, but especially in malaria-endemic settings because the pathogens responsible overlap in clinical presentation and frequently occur together. Rapid identification of bacterial pneumonia with high-quality diagnostic tools would enable appropriate, point-of-care antibiotic treatment. Current diagnostics are insufficient, and the discovery and development of new tools is needed. We report a unique biomarker signature identified in blood samples to accomplish this. Blood samples from 195 pediatric Mozambican patients with clinical pneumonia were analyzed with an aptamer-based, high-dynamic-range, quantitative assay (~1200 proteins). We identified new biomarkers using a training set of samples from patients with established bacterial, viral, or malarial pneumonia. Proteins with significantly variable abundance across etiologies (false discovery rate <0.01) formed the basis for predictive diagnostic models derived from machine learning techniques (Random Forest, Elastic Net). Validation on a dedicated test set of samples was performed. Significantly different abundances between bacterial and viral infections (219 proteins) and bacterial infections and mixed (viral and malaria) infections (151 proteins) were found. Predictive models achieved >90% sensitivity and >80% specificity, regardless of number of pathogen classes. Bacterial pneumonia was strongly associated with neutrophil markers-in particular, degranulation including HP, LCN2, LTF, MPO, MMP8, PGLYRP1, RETN, SERPINA1, S100A9, and SLPI. Blood protein signatures highly associated with neutrophil biology reliably differentiated bacterial pneumonia from other causes. With appropriate technology, these markers could provide the basis for a rapid diagnostic for field-based triage for antibiotic treatment of pediatric pneumonia.

Sections du résumé

BACKGROUND
Differential etiologies of pediatric acute febrile respiratory illness pose challenges for all populations globally, but especially in malaria-endemic settings because the pathogens responsible overlap in clinical presentation and frequently occur together. Rapid identification of bacterial pneumonia with high-quality diagnostic tools would enable appropriate, point-of-care antibiotic treatment. Current diagnostics are insufficient, and the discovery and development of new tools is needed. We report a unique biomarker signature identified in blood samples to accomplish this.
METHODS
Blood samples from 195 pediatric Mozambican patients with clinical pneumonia were analyzed with an aptamer-based, high-dynamic-range, quantitative assay (~1200 proteins). We identified new biomarkers using a training set of samples from patients with established bacterial, viral, or malarial pneumonia. Proteins with significantly variable abundance across etiologies (false discovery rate <0.01) formed the basis for predictive diagnostic models derived from machine learning techniques (Random Forest, Elastic Net). Validation on a dedicated test set of samples was performed.
RESULTS
Significantly different abundances between bacterial and viral infections (219 proteins) and bacterial infections and mixed (viral and malaria) infections (151 proteins) were found. Predictive models achieved >90% sensitivity and >80% specificity, regardless of number of pathogen classes. Bacterial pneumonia was strongly associated with neutrophil markers-in particular, degranulation including HP, LCN2, LTF, MPO, MMP8, PGLYRP1, RETN, SERPINA1, S100A9, and SLPI.
CONCLUSIONS
Blood protein signatures highly associated with neutrophil biology reliably differentiated bacterial pneumonia from other causes. With appropriate technology, these markers could provide the basis for a rapid diagnostic for field-based triage for antibiotic treatment of pediatric pneumonia.

Identifiants

pubmed: 33534888
pii: 6127315
doi: 10.1093/cid/ciaa1843
pmc: PMC8653634
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3939-e3948

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : OPP50092
Organisme : "Centro de Excelencia Severo Ochoa 2019-2023" Program
ID : CEX2018-000806-S

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Public Health Nutr. 2013 Sep;16(9):1565-74
pubmed: 23635423
PLoS One. 2016 Aug 25;11(8):e0161721
pubmed: 27559728
Pediatr Pulmonol. 2012 Apr;47(4):386-92
pubmed: 21916025
Ann Am Thorac Soc. 2016 Aug;13 Suppl 4:S297-304
pubmed: 27564664
J Infect Dis. 2017 Jan 15;215(2):312-320
pubmed: 27837008
BMC Infect Dis. 2016 Jul 08;16:317
pubmed: 27391033
Infection. 2017 Jun;45(3):299-307
pubmed: 27995553
Lancet. 2004 Oct 16-22;364(9443):1411-20
pubmed: 15488216
Sci Rep. 2017 Jul 26;7(1):6548
pubmed: 28747714
BMC Med. 2014 Feb 19;12:31
pubmed: 24548672
HIV Med. 2012 Nov;13(10):581-8
pubmed: 22500780
Malar J. 2014 Oct 13;13:400
pubmed: 25311375
Proc Natl Acad Sci U S A. 1986 Sep;83(18):6692-6
pubmed: 3462719
PLoS One. 2018 Aug 16;13(8):e0201349
pubmed: 30114193
Exp Ther Med. 2018 Aug;16(2):758-766
pubmed: 30112034
Bull World Health Organ. 2005 May;83(5):353-9
pubmed: 15976876
Lancet Infect Dis. 2017 Nov;17(11):1133-1161
pubmed: 28843578
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Blood. 1991 Jun 15;77(12):2724-30
pubmed: 2043769
PLoS One. 2016 Mar 22;11(3):e0152020
pubmed: 27002977
Am J Respir Crit Care Med. 2016 Feb 15;193(4):448-59
pubmed: 26469764

Auteurs

Michael A Gillette (MA)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

D R Mani (DR)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Christopher Uschnig (C)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard T. H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, Massachusetts, USA.

Karell G Pellé (KG)

Harvard T. H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, Massachusetts, USA.

Lola Madrid (L)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Sozinho Acácio (S)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Miguel Lanaspa (M)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Pedro Alonso (P)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Clarissa Valim (C)

Harvard T. H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, Massachusetts, USA.
Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

Steven A Carr (SA)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Stephen F Schaffner (SF)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard T. H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, Massachusetts, USA.

Bronwyn MacInnis (B)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard T. H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, Massachusetts, USA.

Danny A Milner (DA)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Harvard T. H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, Massachusetts, USA.
American Society for Clinical Pathology, Chicago, Illinois, USA.

Quique Bassat (Q)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Catalan Institution for Research and Advanced Studies (ICREA) Barcelona, Spain.
Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu (University of Barcelona), Barcelona, Spain.
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Dyann F Wirth (DF)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard T. H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH